期刊
EMBO JOURNAL
卷 30, 期 13, 页码 2719-2733出版社
WILEY
DOI: 10.1038/emboj.2011.158
关键词
androgen receptor; chromatin; metabolism; prostate cancer; transcription
资金
- NIHR Cambridge Biomedical Research Centre
- DOH HTA
- MRC
- CRUK
- University of Cambridge
- Cancer Research UK
- Hutchison Whampoa Limited
- MRC [G0900871] Funding Source: UKRI
- Cancer Research UK [19556, 11562] Funding Source: researchfish
- Medical Research Council [G0900871] Funding Source: researchfish
- Novo Nordisk Fonden [NNF11OC1014864] Funding Source: researchfish
The androgen receptor (AR) is a key regulator of prostate growth and the principal drug target for the treatment of prostate cancer. Previous studies have mapped AR targets and identified some candidates which may contribute to cancer progression, but did not characterize AR biology in an integrated manner. In this study, we took an interdisciplinary approach, integrating detailed genomic studies with metabolomic profiling and identify an anabolic transcriptional network involving AR as the core regulator. Restricting flux through anabolic pathways is an attractive approach to deprive tumours of the building blocks needed to sustain tumour growth. Therefore, we searched for targets of the AR that may contribute to these anabolic processes and could be amenable to therapeutic intervention by virtue of differential expression in prostate tumours. This highlighted calcium/calmodulin-dependent protein kinase kinase 2, which we show is overexpressed in prostate cancer and regulates cancer cell growth via its unexpected role as a hormone-dependent modulator of anabolic metabolism. In conclusion, it is possible to progress from transcriptional studies to a promising therapeutic target by taking an unbiased interdisciplinary approach. The EMBO Journal (2011) 30, 2719-2733. doi:10.1038/emboj.2011.158; Published online 20 May 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据